Silencing α-synuclein gene expression enhances tyrosine hydroxylase activity in MN9D cells

Neurochemical Research

Volumn 33, Issue 7, 2008, Pages 1401-1409

  Liu, Dongmei ^a   Jin, Ling ^a   Wang, Hao ^a   Zhao, Huanying ^a   Zhao, Chunli ^a   Duan, Chunli ^a   Lu, Lingling ^a   Wu, Bo ^a   Yu, Shun ^b   Chan, Piu ^b   Li, Yaohua ^b   Yang, Hui ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Synuclein; Dopamine; Parkinson's disease; RNA interference

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; LEVODOPA; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOSOL; DNA METABOLISM; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE SILENCING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; RNA INTERFERENCE;

ALPHA-SYNUCLEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; DOWN-REGULATION; FLUORESCENT ANTIBODY TECHNIQUE; GENE SILENCING; HUMANS; LEVODOPA; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSFECTION; TYROSINE 3-MONOOXYGENASE;

EID: 44449179948     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-008-9599-7     Document Type: Article

References (42)

1. Abeliovich A, Schmitz Y, Farinas I et al (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25:239-252
2. Baba M, Nakajo S, Tu PH et al (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152:879-884
3. Baptista MJ, O'Farrell C, Daya S et al (2003) Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. J Neurochem 85:957-968
4. Ben-Shachar D, Zuk R, Gazawi H et al (2004) Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders. Biochem Pharmacol 67:1965-1974
5. Berman SB, Hastings TG (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem 73:1127-1137
6. Berresheim U, Kuhn DM (1994) Dephosphorylation of tyrosine hydroxylase by brain protein phosphatases: a predominant role for type 2A. Brain Res 637:273-276
7. Brummelkamp TR, Bernards R, Agami RA (2002) System for stable expression of short interfering RNAs in mammalian cells. Science 296:550-553
8. Choi HK, Won LA, Kontur PJ et al (1991) Immortalization of embryonic mesencephalic dopaminergic neurons by somatic cell fusion. Brain Res 552:67-76
9. Drolet RE, Behrouz B, Lookingland KJ et al (2006) Substrate-mediated enhancement of phosphorylated tyrosine hydroxylase in nigrostriatal dopamine neurons: evidence for a role of alpha-synuclein. J Neurochem 96:950-959
10. Dykxhoorn DM, Novina CD, Sharp PA (2003) Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 4:457-467
11. Elbashir SM, Lendeckel W, Tuschl T et al (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15:188-200
12. Fire A, Xu S, Montgomery MK et al (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-811
13. 2 and hydroxyl radicals but not glutathione-protein-mixed disulfides. J Neurochem 82:66-74
14. Greenbaum EA, Graves CL, Mishizen-Eberz AJ et al (2005) The E46K mutation in alpha-synuclein increases amyloid fibril formation. J Biol Chem 280:7800-7807
15. Kruger R, Kuhn W, Muller T et al (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18:106-108
16. LaVoie MJ, Hastings TG (1999) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci 19:1484-1491
17. Lotharius J, Brundin P (2002) Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet 11:2395-2407
18. Lotharius J, Brundin P (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 3:932-942
19. Lykkebo S, Jensen PH (2002) Alpha-synuclein and presynaptic function: implications for Parkinson's disease. Neuromolecular Med 2:115-129
20. Martin FL, Williamson SJ, Paleologou KE et al (2004) Alpha-synuclein and the pathogenesis of Parkinson's disease. Protein Pept Lett 11:229-237
21. Mezey E, Dehejia AM, Tresser N et al (1998) Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease. Mol Psychiatry 3:493-499
22. Ostrerova N, Petrucelli L, Farrer M et al (1999) Alpha-synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 19:5782-5791
23. Paddison PJ, Caudy AA, Bernstein E et al (2002) Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 16:948-958
24. Peng X, Tehranian R, Perez RG et al (2005) Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J Cell Sci 118:3523-3530
25. Perez RG, Hastings TG (2004) Could a loss of alpha-synuclein function put dopaminergic neurons at risk? J Neurochem 89:1318-1324
26. Perez RG, Waymire JC, Lin E et al (2002) A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 22:3090-3099
27. Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047
28. Rajagopalan S, Andersen JK (2001) Alpha-synuclein aggregation: is it the toxic gain of function responsible for neurodegeneration in Parkinson's disease? Mech Ageing Dev 122:1499-1510
29. Ramsey AJ, Hillas PJ, Fitzpatrick PF (1996) Characterization of the active site iron in tyrosine hydroxylase: redox states of the iron. J Biol Chem 271:24395-24400
30. Recchia A, Debetto P, Negro A et al (2004) Alpha-synuclein and Parkinson's disease. FASEB J 18:617-626
31. Rochet JC, Outeiro TF, Conway KA et al (2004) Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci 23:23-34
32. Sidhu A, Wersinger C, Vernier P (2004) Alpha-synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. FEBS Lett 565:1-5
33. Sidhu A, Wersinger C, Vernier P (2004) Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J 18:637-647
34. Spillantini MG, Schmidt ML, Lee VM et al (1997) Alpha-synuclein in Lewy bodies. Nature 388:839-840
35. Stokes AH, Hastings TG, Vrana KE et al (1999) Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 55:659-665
36. Tabner BJ, Turnbull S, El-Agnaf OM et al (2002) Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic Biol Med 32:1076-1083
37. Vrana KE (1996) Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 67:443-462
38. Wersinger C, Sidhu A (2003) Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci Lett 340:189-192
39. 2 in a human neuroblastoma divided cell line transfected with alpha-synuclein and its familial Parkinson's disease-linked mutants. Neurosci Lett 342:124-128
40. Yavich L, Tanila H, Vepsalainen S et al (2004) Role of alpha-synuclein in presynaptic dopamine recruitment. J Neurosci 24:11165-11170
41. Yu S, Ueda K, Chan P (2005) Alpha-synuclein and dopamine metabolism. Mol Neurobiol 31:243-254
42. Yu S, Zuo X, Li Y et al (2004) Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells. Neurosci Lett 367:34-39